Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: Impact of TKIs' antiangiogenic activity - Abstract

Cardiac metastasis from renal cell carcinoma, especially without neoplastic thrombosis of the vena cava, is extremely rare.

The prognosis of patients with metastatic renal cell carcinoma has been radically influenced by the introduction of tyrosine kinase inhibitors, but very few reports in the literature have described their activity in heart metastasis. We report the case of a woman with a left ventricle metastasis from kidney cancer without renal vein involvement, who was treated with pazopanib. The patient achieved a prolonged partial response, with clear signs of metastasis devascularization and a favorable toxicity profile.

Written by:
Schinzari G, Monterisi S, Signorelli D, Cona S, Cassano A, Danza F, Barone C.   Are you the author?

Reference: Tumori. 2014 Nov-Dec;100(6):e298-300.
doi: 10.1700/1778.19304


PubMed Abstract
PMID: 25688515

UroToday.com Renal Cancer Section